Moderna (NASDAQ:MRNA) Issues Earnings Results

Moderna (NASDAQ:MRNA) issued its quarterly earnings results on Friday. The company reported ($3.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.02) by ($0.38), Briefing.com reports. Moderna had a negative return on equity of 30.15% and a negative net margin of 145.16%.The business had revenue of $389.00 million during the quarter, compared to analyst estimates of $236.37 million. During the same period in the previous year, the business posted ($2.52) earnings per share. The firm’s quarterly revenue was up 260.2% on a year-over-year basis.

Here are the key takeaways from Moderna’s conference call:

• Q1 revenue of $400 million (driven by U.K. strategic partnerships) and a reiteration of up to 10% revenue growth for 2026, alongside a 26% year‑over‑year reduction in adjusted cash cost and ending cash/investments of $7.5 billion.
• Moderna recorded an $878 million cost‑of‑sales charge from a settlement and will make a lump sum payment of $950 million in Q3 2026, with a contingent additional payment of up to $1.3 billion if the Federal Circuit affirms liability under Section 1498; the company plans to appeal and views further payment as not probable.
• Regulatory and commercial momentum in Europe with EU approvals for mCOMBRIAX (the world’s first flu+COVID combo) and Spikevax, and a U.S. PDUFA date of August 5 for the seasonal flu vaccine mRNA‑1010, expected to help drive EU growth in 2027.
• Pipeline advancement with initiation of a phase III intismeran trial in high‑risk stage 1 non‑small cell lung cancer (including a monotherapy arm), an interim 5‑year update for intismeran in adjuvant melanoma due at ASCO, a fully enrolled phase III norovirus study and a pivotal readout for propionic acidemia expected in 2026.

Moderna Stock Performance

NASDAQ MRNA opened at $45.37 on Friday. The firm has a market capitalization of $17.92 billion, a P/E ratio of -6.24 and a beta of 1.06. Moderna has a 1-year low of $22.28 and a 1-year high of $59.55. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.29 and a quick ratio of 3.22. The business’s 50-day simple moving average is $51.84 and its 200-day simple moving average is $39.29.

Insider Buying and Selling at Moderna

In other news, President Stephen Hoge sold 160,009 shares of Moderna stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $48.84, for a total value of $7,814,839.56. Following the transaction, the president directly owned 1,457,427 shares of the company’s stock, valued at $71,180,734.68. The trade was a 9.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 10.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Moderna

Several hedge funds have recently modified their holdings of MRNA. AQR Capital Management LLC purchased a new stake in shares of Moderna during the 1st quarter valued at about $415,000. NewEdge Advisors LLC raised its holdings in shares of Moderna by 732.7% during the 1st quarter. NewEdge Advisors LLC now owns 11,575 shares of the company’s stock valued at $328,000 after buying an additional 10,185 shares during the period. United Services Automobile Association purchased a new stake in shares of Moderna during the 1st quarter valued at about $230,000. Focus Partners Wealth raised its holdings in shares of Moderna by 58.7% during the 1st quarter. Focus Partners Wealth now owns 23,547 shares of the company’s stock valued at $668,000 after buying an additional 8,706 shares during the period. Finally, American Century Companies Inc. raised its holdings in shares of Moderna by 5.2% during the 2nd quarter. American Century Companies Inc. now owns 48,859 shares of the company’s stock valued at $1,348,000 after buying an additional 2,410 shares during the period. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have issued reports on MRNA shares. Wall Street Zen raised Moderna from a “sell” rating to a “hold” rating in a research note on Saturday, January 17th. TD Cowen reissued a “hold” rating on shares of Moderna in a research note on Thursday, January 29th. The Goldman Sachs Group reissued a “neutral” rating and issued a $49.00 price target on shares of Moderna in a research note on Friday. Jefferies Financial Group set a $37.00 price objective on Moderna and gave the company a “hold” rating in a research note on Tuesday, March 3rd. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $45.00 price objective on shares of Moderna in a research note on Tuesday, February 17th. Two equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and five have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Moderna currently has an average rating of “Reduce” and a consensus price target of $34.60.

Moderna News Summary

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Q1 revenue sharply exceeded estimates — $389M (+~260% YoY) driven by strong international COVID‑19 vaccine sales, showing demand outside the U.S. and a meaningful top‑line rebound. Article Title
• Positive Sentiment: Pipeline and upcoming regulatory catalysts remain market drivers — the mRNA‑1010 seasonal flu PDUFA (Aug. 5) and advancing oncology programs give upside optionality beyond COVID vaccines. Article Title
• Neutral Sentiment: Company reiterated 2026 outlook (up to ~10% revenue growth) and signaled continued operating expense reductions excluding the non‑recurring settlement — suggests management expects sustainable margin improvements over time. Article Title
• Neutral Sentiment: Revenue concentration shifted heavily to ex‑U.S. markets (~80% of Q1 revenue), which helped the beat but increases sensitivity to international procurement cycles and government deals. Article Title
• Negative Sentiment: A $0.9B one‑time litigation settlement was recorded in Q1, producing a wider GAAP loss (GAAP EPS of $(3.40)) and negative gross/net margins — this sizable charge weighed on the earnings print despite the revenue beat. Article Title
• Negative Sentiment: Stock reaction was volatile — shares initially rallied on the revenue beat but later moved lower as investors digested the settlement, continued unprofitability, and reliance on a few government contracts. Article Title

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.